Major Depressive Disorder (MDD)
Major Depressive Disorder (MDD) represents a significant mental health challenge, with emerging research into the efficacy of psychedelics like psilocybin and ketamine offering new avenues for treatment. Recent studies have demonstrated the potential of these compounds to alleviate symptoms, particularly in treatment-resistant cases of MDD.
Key Insights
- 1
Recent trials indicate that psilocybin can produce significant improvements in depressive symptoms with effects lasting up to six months.
- 2
Studies suggest that the response to psychedelics may vary significantly based on dosage and therapeutic context, highlighting the importance of tailored approaches.
- 3
Ketamine has emerged as a rapid-acting treatment option for MDD, showing effects within hours.
- 4
Research is increasingly focused on the mechanisms of action of psychedelics, revealing potential pathways connecting these compounds to neurogenesis and mood regulation.
- 5
Combining psychedelics with psychotherapy may enhance treatment outcomes and sustainability of benefits.
What is Major Depressive Disorder (MDD)?
Major Depressive Disorder (MDD) is characterised by persistent feelings of sadness, loss of interest, and a variety of emotional and physical problems. It impacts daily functioning and is often accompanied by a range of symptoms, including fatigue, altered sleep patterns, appetite disturbances, and cognitive difficulties.
The underlying pathophysiology of MDD is complex and multifactorial, involving neurotransmitter imbalances (such as serotonin and norepinephrine), neuroinflammation, and dysregulation of the neuroendocrine system. Genetic, psychosocial, and environmental factors further contribute to its development.
MDD can lead to significant impairment in personal, social, and occupational domains, and it poses a serious risk factor for suicide. Current estimates indicate it affects a substantial global population, with many individuals remaining untreated or inadequately treated.
Current Treatments
Standard treatments for MDD typically include antidepressants (such as SSRIs and SNRIs), psychotherapy (including cognitive-behavioural therapy), and in some cases, electroconvulsive therapy (ECT) for severe cases. Treatment-resistant MDD often necessitates more complex approaches.
Psychedelic Effect Matrix
Compound efficacy and evidence levels for Major Depressive Disorder (MDD).
| Compound | Magnitude | Evidence | Consistency |
|---|---|---|---|
| Psilocybin Psilocybin demonstrates reliable efficacy in clinical studies for reducing depressive symptoms. | Large | High | Consistent |
| Ketamine Ketamine offers rapid relief from depressive symptoms, particularly in treatment-resistant cases. | Large | High | Consistent |
| MDMA While promising in PTSD, the effects on MDD are less consistently reported. | Medium | Moderate | Inconsistent |
| Ayahuasca Initial findings support anxiety and mood improvement; however, larger studies are needed. | Medium | Moderate | Inconsistent |
| Ibogaine Limited research exists; primarily investigated for substance use disorders. | Small | Low | Inconsistent |
Psilocybin and Major Depressive Disorder (MDD)
Psilocybin, a naturally occurring psychedelic compound, has shown significant promise in alleviating depressive symptoms. Clinical trials indicate that psilocybin can lead to substantial reductions in depression and anxiety, often following a structured therapeutic protocol that combines the compound with psychotherapy. Its rapid onset and durable effects, particularly in treatment-resistant cases, have spurred interest in further exploration of its mechanisms and optimal clinical applications.
Ketamine and Major Depressive Disorder (MDD)
Ketamine, originally developed as an anaesthetic, has been repurposed to treat major depressive disorder due to its rapid antidepressant effects. Administered in sub-anesthesia doses, ketamine can produce marked improvements in depressive symptoms within hours, a stark contrast to the often delayed response seen with traditional antidepressants. Ongoing studies are investigating its long-term efficacy and the potential for developing ketamine-based protocols for chronic depression.
Clinical Outlook
The future of psychedelic treatment for MDD appears promising, especially as ongoing and future clinical trials continue to refine dosing strategies and therapeutic combinations. The integration of psychedelics into mental health care could represent a paradigm shift, providing novel solutions for those with treatment-resistant forms of the disorder.
Industrial Landscape
Key players in this research space include organisations such as the Multidisciplinary Association for Psychedelic Studies (MAPS), the Beckley Foundation, and various academic institutions conducting clinical trials in psychedelic therapy.
Quick Indicators
Related Topics
Organisations
Search →Janssen Research & Development
Janssen Research & Development is the pharmaceutical research and development arm of Johnson & Johnson (J&J). Operating under J&J's Innovative Medicine division, Janssen has sponsored clinical trials into ketamine-derived compounds, including esketamine (Spravato), the first FDA-approved psychedelic-adjacent treatment for treatment-resistant depression.
Clexio Biosciences
Clexio Biosciences is a private Israeli clinical-stage CNS company founded in 2018 by Teva Pharmaceuticals R&D veterans. Their lead programme CLE-100 is a once-daily oral tablet formulation of esketamine for MDD — distinguished from the FDA-approved Spravato (intranasal, in-clinic) by enabling outpatient, at-home use. Phase 2 CLEO study results showed a promising safety profile and encouraging efficacy specifically in post-COVID MDD subgroups; the Phase 2 SOLEO study (NCT06340958, higher dose, stricter treatment-resistance criteria) enrolled first patients April 2024 and reached 50% enrollment by December 2024. CLE-100 holds multiple US method-of-use patents (2024). In December 2025, Clexio spun out its muscarinic agonist programme (CLE-905) into a new entity, Syremis Therapeutics, which raised $165M Series A co-led by Dexcel Pharma and Third Rock Ventures. Co-founders Kogan, Levy, and Kagan simultaneously lead Syremis; Clexio continues independently with CLE-100 and preclinical CLE-043.
Cybin
Cybin Inc. (founded 2019) is a Canadian clinical-stage biopharmaceutical company developing psychedelic-based therapeutics—now operating as Helus Pharma—focused on proprietary novel serotonergic agonists and deuterated psilocin analogs for mental health conditions.
Ohio State University
The Ohio State University is a public land-grant research university based in Columbus, Ohio, offering undergraduate, graduate, and professional programs and conducting research across many fields. It was founded as the Ohio Agricultural and Mechanical College and serves as a major educational and economic institution in Ohio.
COMPASS Pathways
COMPASS Pathways is a UK-listed biopharmaceutical company developing COMP360 synthetic psilocybin therapy for treatment-resistant depression, with two successful Phase 3 trials making it the leading candidate for the first regulatory approval of a classic psychedelic medicine.
Definium Therapeutics
Definium Therapeutics (formerly Mind Medicine / MindMed) is a late-stage clinical biopharmaceutical company headquartered in New York, founded in 2019 and rebranded in January 2026. Led by CEO Robert Barrow, the company applies scientific rigor to psychedelic-derived molecules to develop accessible, rapidly-acting psychiatric treatments. Its lead asset, DT120 ODT (formerly MM-120) — a pharmaceutically optimised formulation of lysergide D-tartrate (LSD) as an orally disintegrating tablet — has received FDA Breakthrough Therapy Designation for generalised anxiety disorder (GAD) and delivered compelling Phase 2b results: 65% clinical response rate and 48% remission at 12 weeks following a single dose. Three Phase 3 trials are currently underway: Voyage and Panorama (GAD) and Emerge (MDD, fully enrolled). Topline data from all three studies is expected in 2026, potentially positioning Definium for the first-ever FDA approval of an LSD-derived therapy. A second pipeline asset, DT402 (formerly MM402) — an MDMA-related compound — is in Phase 1 development for autism spectrum disorder.
National Institute on Drug Abuse (NIDA)
U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.
Delix Therapeutics
Delix Therapeutics is harnessing the power of neuroplastogens, a novel class of compounds designed to bring about a new paradigm in brain health therapeutics with treatments intended to be safe, fast-acting, and long-lasting. Through its discovery platform, Delix has identified non-hallucinogenic versions of psychedelic compounds with favorable safety and therapeutic profiles. The company was co-founded in 2019 by David E. Olson and Nick Haft, building upon Olson's discovery at the University of California, Davis, of several novel psychoplastogens that have significant therapeutic potential in preclinical models, without hallucinogenic side effects. Delix's treatments are designed to address the root cause of neuropsychiatric conditions by repairing the underlying synaptic damage through targeted neuroplasticity. To date, the company has synthesized over 2000 novel psychoplastogens, many of which are analogs of known psychedelics such as ibogaine and 5-MeO-DMT. Their lead compound, zalsupindole (DLX-001), produces the same rapid and sustained structural and functional plasticity as ketamine, psilocybin, and DMT, without inducing hallucinations or dissociation. Recent Phase I data have demonstrated that DLX-001 is associated with robust signs of CNS engagement and a favorable safety and tolerability profile, with no serious adverse events reported to date. The company's compounds are tailored for swift neuronal repair and can be taken at-home, providing significant advantages to patients, their loved ones, and healthcare providers. Delix focuses on developing non-hallucinogenic psychoplastogens as scalable alternatives to first-generation hallucinogenic psychoplastogens like ketamine and psilocybin.
Entheon Biomedical
Canadian psychedelic biotech that sold its DMT Phase 1 clinical trial assets to Cybin in 2022. Following the sale, Entheon has operated as a near-shell company with minimal employees and no active drug development programme.
National Institute of Mental Health (NIMH)
U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.
Florida International University
Miami public research university where Dr. Jerry B. Brown has taught interdisciplinary psychedelics courses since 1975, and Professor Joseph Lichter runs an Honors College Psychedelic Renaissance course covering therapeutic applications of psilocybin, MDMA, and ketamine. FIU also serves as one of 21 sites in a major national psychedelic clinical trial and hosts the Cannadelic conference — the first cannabis and psychedelics conference focused on next-generation research.
University of Amsterdam
The University of Amsterdam (UvA) is one of the Netherlands' leading research universities, with its Amsterdam UMC Department of Psychiatry conducting clinical trials on psilocybin and psychedelic-assisted therapies for treatment-resistant mental health conditions.
People
Search →Robin Murphy
Researcher at the University of Auckland School of Pharmacy
She is a coauthor on multiple human psychedelic studies spanning LSD microdosing, sleep, and psilocybin/escitalopram comparisons, making her part of the team contributing to the modern evidence base for psychedelic medicine.
Hartej Gill
Researcher in mood disorders psychopharmacology at the University of Toronto / University Health Network
Notable for coauthoring multiple reviews and meta-analyses on ketamine, esketamine, suicidality, cognition, and psychedelic drug trials in psychiatric research.
Attila Szabo
Researcher in psychoneuroimmunology and psychedelic science; affiliated with the University of Oslo
He is a notable contributor to psychedelic immunology research, including widely cited work on DMT, 5-MeO-DMT, psilocybin, and immune modulation.
Jeanine Kamphuis
Psychiatrist and researcher at the Department for Mood Disorders, University Hospital Groningen (UMCG)
She studies ketamine, esketamine, and classic psychedelics for treatment-resistant psychiatric disorders, including depression, and is a coauthor on multiple psychedelic/ketamine reviews and clinical studies.
Henrik Jungaberle
Dr. sc. hum., CEO and founder of the MIND Foundation; Head of Development at OVID Clinic Berlin
He is a prominent European psychedelic research and implementation figure contributing to psilocybin clinical trials, harm reduction, and healthcare integration work.
Joost Breeksema
Postdoctoral researcher and Executive Director of the OPEN Foundation
He is a prominent psychedelic researcher and advocate whose work helps shape evidence-based psychedelic policy, ethics, and patient-centered understanding of psychedelic and ketamine/esketamine treatments.
Mathieu Seynaeve
Senior Medical Director and Head of Psychotherapy at Beckley Psytech
He is a clinical development leader behind multiple human studies of 5-MeO-DMT and psilocybin, including trials in alcohol use disorder, treatment-resistant depression, and headache disorders.
Kayla Teopiz
Researcher in psychiatry and ketamine/psychedelic medicine research; likely affiliated with the University of Toronto/Trillium Health Partners research network
Teopiz coauthors multiple systematic reviews and clinical studies on ketamine, esketamine, and psilocybin in depression and suicidality, helping synthesize the evidence base for psychedelic and glutamatergic treatments in psychiatry.
Michiel Van Elk
Associate Professor of Cognitive Psychology at Leiden University
Michiel van Elk is a prominent psychedelic science researcher known for rigorous, skeptical work on psilocybin, microdosing, expectancy effects, and the psychological mechanisms and risks of psychedelic experiences.
Jolien Veraart
Psychiatrist and PhD researcher at the University Medical Center Groningen / University of Groningen
She is a leading clinical researcher on ketamine and oral esketamine for treatment-resistant depression, including safety, efficacy, and real-world implementation.
Philippe Lucas
Director, Research and Safe Access at MAPS
He is a prominent Canadian psychedelic and cannabis researcher whose work has helped establish early evidence on ayahuasca-assisted therapy, psychedelic survey research, and harm-reduction policy.
Joshua Di Vincenzo
MSc researcher / clinical research staff member at the University Health Network and University of Toronto
He coauthors multiple systematic reviews and real-world studies on ketamine for treatment-resistant depression, making him a visible contributor to the evidence base on psychedelic-adjacent psychiatric therapeutics.
Connected Evidence
The latest clinical data and verified academic findings associated with Major Depressive Disorder (MDD).